Award
Delivery Order #SPE2D226F1193
Delivery Order for Ondansetron Hydrochloride Under Long-Term Pharmaceutical Supply Contract
Buyer
Defense Logistics Agency
Award Amount
$10.50
Ceiling
$10.50
Awarded
February 11, 2026
Period of Performance
Feb 11, 2026 – Feb 11, 2026
Identifier
SPE2D226F1193
NAICS
325411
This contract represents a delivery order awarded to DMS Pharmaceutical Group Inc., a well-established pharmaceutical manufacturer and distributor, under an existing indefinite delivery vehicle (IDV) contract. The delivery order involves the procurement of ondansetron hydrochloride, a critical pharmaceutical product used to prevent nausea and vomiting. The award is significant for government healthcare operations, contributing to the sustained availability of essential medications and supporting public health initiatives. The scope of work encompasses the supply of the specified pharmaceutical product to government facilities, ensuring timely and reliable delivery. This delivery order is competitively awarded under the umbrella of the multi-year IDV contract that spans from mid-2025 and supports long-term pharmaceutical supply needs. The performance is scheduled for a single date in early 2026, indicating a focused and specific fulfillment instance within the broader contract framework.
Description
8511914621!ONDANSETRON HYDROCH